Related Experiment Videos
Gatifloxacin Kyorin Pharmaceutical Co
1Taro Pharmaceuticals, 5 Skyline Drive, Hawthorne, NY 10532, USA. wbrown@taropharma.com
Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
Summary
Gatifloxacin, a novel fluoroquinolone antibiotic, is safe and effective for treating various bacterial infections. Its unique structure may reduce resistance development in Gram-positive bacteria.
Area of Science:
- Pharmacology
- Microbiology
Background:
- Gatifloxacin is a novel fluoroquinolone antibiotic.
- It possesses a unique chemical structure with a 3-methylpiperazine group at position 7 and a methoxy group at position 8.
- The 8-methoxy substituent may inhibit the development of resistance in Gram-positive bacteria.
Purpose of the Study:
- To evaluate the safety and efficacy of gatifloxacin.
- To review the approved indications for gatifloxacin treatment.
Main Methods:
- Literature review of clinical studies and regulatory approvals.
- Analysis of gatifloxacin's chemical properties and their impact on resistance.
Main Results:
- Gatifloxacin has demonstrated safety and efficacy in clinical use.
- The antibiotic is approved for treating community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, sinusitis, skin infections, and urinary tract infections.
- It is also indicated for gonorrhea and other specific infections.
Conclusions:
- Gatifloxacin is a safe and effective antibiotic for a range of bacterial infections.
- Its chemical structure may offer an advantage in combating bacterial resistance.